{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:16:43Z","timestamp":1784557003048,"version":"3.55.0"},"reference-count":39,"publisher":"Bioscientifica","issue":"10","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Neuroendocrine tumors (NETs) are rare neoplasms that occur in various locations throughout the body. Despite their usually benign character, they might manifest with distant metastases. N-terminal prohormone of brain natriuretic peptide (NT-proBNP) has previously been described as a useful biomarker in diagnosing carcinoid heart disease (CHD), a common advanced NETs manifestation. We observed plasma concentrations of NT-proBNP in metastatic midgut NETs over a 4-year period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aimed to explore NT-proBNP concentrations in states of varying levels of cell proliferation and disease status. Our goal was to investigate NT-proBNP\u2019s role in predicting disease progression in relation to previous research and up-to-date scientific guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We performed a retrospective multivariate analysis of NT-proBNP concentrations in 41 midgut NETs patients treated with somatostatin analogs, all with liver metastases. NT-proBNP concentrations were measured in every patient across 16 evenly distanced time points over a 48-month period and were compared to variables such as sex, age, grading, Ki-67, primary tumor location, and CT findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>NT-proBNP concentrations correlated positively with higher liver tumor burden, higher grading, high Ki-67 levels, and with progressive disease in CT. There were no differences in NT-proBNP levels with regard to primary location (ileum vs jejunum), sex, and age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We conclude that NT-proBNP is a useful analyte for monitoring NETs progression, due to its increased concentration in scenarios implying increased cellular proliferation. These long-term follow-up results align with previous findings and suggest an additional role for NT-proBNP in diagnostic algorithms, beyond a CHD biomarker.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-23-0249","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T11:48:16Z","timestamp":1691495296000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":7,"title":["NT-proBNP as a neuroendocrine tumor biomarker: beyond heart failure"],"prefix":"10.1530","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6548-0613","authenticated-orcid":true,"given":"Pawe\u0142","family":"Komarnicki","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Gut","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Musia\u0142kiewicz","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Cie\u015blewicz","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1929-3275","authenticated-orcid":true,"given":"George","family":"Mastorakos","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology, Diabetes Mellitus and Metabolism, Aretaieion University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Rucha\u0142a","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","first-page":"394","article-title":"Guidelines for the diagnosis and treatment of neuroendocrine","volume":"80","author":"Rindi","year":"2005","unstructured":"Rindi GArnold REriksson BKrenning EPHerder De WWGoede ACaplin MReubi JCNilsson OFave GD, et al. Guidelines for the diagnosis and treatment of neuroendocrine. 200580394\u2013424. (https:\/\/doi.org\/10.1159\/000085237)"},{"key":"bib2","series-title":"Current Oncology Reports","first-page":"43","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","author":"Das","year":"2021","unstructured":"Das S & Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?Current Oncology Reports20212343. (https:\/\/doi.org\/10.1007\/s11912-021-01029-7)"},{"key":"bib3","series-title":"JAMA Oncology","first-page":"1335","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","unstructured":"Dasari AShen CHalperin DZhao BZhou S & Xu Y. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncology201731335\u20131342. (https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589)"},{"key":"bib4","series-title":"Science","first-page":"628","article-title":"Specific endocrine tissue marker defined by a monoclonal antibody","volume":"222","author":"Lloyd","year":"1983","unstructured":"Lloyd RV. & Wilson BS. Specific endocrine tissue marker defined by a monoclonal antibody. Science1983222628\u2013630. (https:\/\/doi.org\/10.1126\/science.6635661)"},{"key":"bib5","series-title":"Polish Archives of Internal Medicine","first-page":"903","article-title":"Assessment of serotonin concentration in patients with a smallintestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues","volume":"130","author":"Gut","year":"2020","unstructured":"Gut PCzarnywojtek ASawickaGutaj N & Rucha\u0142a M. Assessment of serotonin concentration in patients with a smallintestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues. Polish Archives of Internal Medicine2020130903\u2013905. (https:\/\/doi.org\/10.20452\/pamw.15504)"},{"key":"bib6","series-title":"Histopathology","first-page":"147","article-title":"PGP 9.5, a new marker for human neuroendocrine tumours","volume":"9","author":"Rode","year":"1985","unstructured":"Rode JDhillon APDoran JFJackson P & Thompson RJ. PGP 9.5, a new marker for human neuroendocrine tumours. Histopathology19859147\u2013158. (https:\/\/doi.org\/10.1111\/j.1365-2559.1985.tb02431.x)"},{"key":"bib7","series-title":"Endokrynologia Polska","first-page":"308","article-title":"Determination of neuron-specific enolase in patients with midgut-type tumour treated with somatostatin analogues","volume":"72","author":"Gut","year":"2021","unstructured":"Gut PCzarnywojtek ASawicka-Gutaj NWoli\u0144ski KMaciejewski AKomarnicki P & Rucha\u0142a M. Determination of neuron-specific enolase in patients with midgut-type tumour treated with somatostatin analogues. Endokrynologia Polska202172308\u2013318. (https:\/\/doi.org\/10.5603\/EP.a2021.0060)"},{"key":"bib8","series-title":"International Journal of Biological Markers","first-page":"160","article-title":"Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings","volume":"14","author":"Giovanella","year":"1999","unstructured":"Giovanella LLa SCeriani LUccella SErba P & Garancini S. Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings. International Journal of Biological Markers199914160\u2013166. (https:\/\/doi.org\/10.1177\/172460089901400307)"},{"key":"bib9","series-title":"Journal of Clinical Medicine","article-title":"Circulating neuroendocrine tumor biomarkers: past, present and future","volume":"11","author":"Komarnicki","year":"2022","unstructured":"Komarnicki PMusia\u0142kiewicz JSta\u0144ska AMaciejewski AGut PMastorakos G & Rucha\u0142a M. Circulating neuroendocrine tumor biomarkers: past, present and future. Journal of Clinical Medicine202211. (https:\/\/doi.org\/10.3390\/jcm11195542)"},{"key":"bib10","series-title":"Neuroendocrinology","first-page":"157","article-title":"Enets consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary","volume":"95","author":"Pavel","year":"2012","unstructured":"Pavel MBaudin ECouvelard AKrenning E\u00d6berg KSteinm\u00fcller TAnlauf MWiedenmann BSalazar R & Barcelona Consensus Conference participants. Enets consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology201295157\u2013176. (https:\/\/doi.org\/10.1159\/000335597)"},{"key":"bib11","series-title":"Hepatobiliary Surgery and Nutrition","first-page":"440","article-title":"Neuroendocrine liver metastases: a contemporary review of treatment strategies","volume":"9","author":"Cloyd","year":"2020","unstructured":"Cloyd JMEjaz AKonda BMakary MS & Pawlik TM. Neuroendocrine liver metastases: a contemporary review of treatment strategies. Hepatobiliary Surgery and Nutrition20209440\u2013451. (https:\/\/doi.org\/10.21037\/hbsn.2020.04.02)"},{"key":"bib12","series-title":"Lancet Oncology","first-page":"e8","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","unstructured":"Frilling AModlin IMKidd MRussell CBreitenstein SSalem RKwekkeboom DLau W-YKlersy CVilgrain V, Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncology201415e8\u2013e21. (https:\/\/doi.org\/10.1016\/S1470-2045(1370362-0)"},{"key":"bib13","series-title":"Journal of Clinical Oncology","first-page":"4656","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","unstructured":"Rinke AM\u00fcller HHSchade-Brittinger CKlose KJBarth PWied MMayer CAminossadati BPape UFBl\u00e4ker M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology2009274656\u20134663. (https:\/\/doi.org\/10.1200\/JCO.2009.22.8510)"},{"key":"bib14","series-title":"Surgery","first-page":"657","article-title":"Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection","volume":"165","author":"Kimbrough","year":"2019","unstructured":"Kimbrough CWBeal EWDillhoff MESchmidt CRPawlik TMLopez-Aguiar AGPoultsides GMakris ERocha FGCrown A, et al. Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. Surgery2019165657\u2013663. (https:\/\/doi.org\/10.1016\/j.surg.2018.09.008)"},{"key":"bib15","series-title":"Journal of Neuroendocrinology","first-page":"e13146","article-title":"European Neuroendocrine Tumor Society (ENETS) 2022 Guidance paper for carcinoid syndrome and carcinoid heart disease","volume":"34","author":"Grozinsky-Glasberg","year":"2022","unstructured":"Grozinsky-Glasberg SDavar JHofland JDobson RPrasad VPascher ADenecke TTesselaar METPanzuto FAlb\u00e5ge A, et al. European Neuroendocrine Tumor Society (ENETS) 2022 Guidance paper for carcinoid syndrome and carcinoid heart disease. Journal of Neuroendocrinology202234e13146. (https:\/\/doi.org\/10.1111\/jne.13146)"},{"issue":"Supplement 1","key":"bib16","series-title":"Clinics","first-page":"e490s","article-title":"Carcinoid syndrome: update on the pathophysiology and treatment","volume":"73","author":"Rubin de Celis Ferrari","year":"2018","unstructured":"Rubin de Celis Ferrari ACGlasberg J & Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics201873(Supplement 1) e490s. (https:\/\/doi.org\/10.6061\/clinics\/2018\/e490s)"},{"key":"bib17","series-title":"Lancet Oncology","first-page":"525","article-title":"The frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a large population-based study using SEER-Medicare data","volume":"18","author":"Leong","year":"2017","unstructured":"Leong JYAmir S & Patel RR. The frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a large population-based study using SEER-Medicare data. Lancet Oncology201718525\u2013534. (https:\/\/doi.org\/10.1016\/S1470-2045(1730110-9.The)"},{"key":"bib18","series-title":"Journal of the American College of Cardiology","first-page":"1288","article-title":"Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement","volume":"69","author":"Davar","year":"2017","unstructured":"Davar JConnolly HMCaplin MEPavel MZacks JBhattacharyya SCuthbertson DJDobson RGrozinsky-Glasberg SSteeds RP, et al. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement. Journal of the American College of Cardiology2017691288\u20131304. (https:\/\/doi.org\/10.1016\/j.jacc.2016.12.030)"},{"key":"bib19","series-title":"Endocrinology and Metabolism Clinics of North America","first-page":"671","article-title":"Carcinoid heart disease: a review","volume":"47","author":"Hayes","year":"2018","unstructured":"Hayes ARDavar J & Caplin ME. Carcinoid heart disease: a review. Endocrinology and Metabolism Clinics of North America201847671\u2013682. (https:\/\/doi.org\/10.1016\/j.ecl.2018.04.012)"},{"issue":"Supplement 1","key":"bib20","series-title":"Congestive Heart Failure (Greenwich, Conn.)","first-page":"3","article-title":"B-type natriuretic peptide: the level and the drug--partners in the diagnosis of congestive heart failure","volume":"10","author":"Bhalla","year":"2004","unstructured":"Bhalla VWillis S & Maisel AS. B-type natriuretic peptide: the level and the drug--partners in the diagnosis of congestive heart failure. Congestive Heart Failure (Greenwich, Conn.)200410(Supplement 1) 3\u201327. (https:\/\/doi.org\/10.1111\/j.1527-5299.2004.03310.x)"},{"key":"bib21","series-title":"Endokrynologia Polska","first-page":"549","article-title":"Neuroendocrine neoplasms of the small intestine and the appendix - Update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours)","volume":"73","author":"Bednarczuk","year":"2022","unstructured":"Bednarczuk TZemczak ABolanowski MBorowska MChmielik ECwikla JBFoltyn WGisterek IHandkiewicz-Junak DHubalewska-Dydejczyk A, et al. Neuroendocrine neoplasms of the small intestine and the appendix - Update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynologia Polska202273549\u2013583. (https:\/\/doi.org\/10.5603\/EP.a2022.0052)"},{"key":"bib22","series-title":"Clinical Medicine Insights. Cardiology","first-page":"1179546820968101","article-title":"Carcinoid Heart Disease: How to Diagnose and Treat in 2020?","volume":"14","author":"Bober","year":"2020","unstructured":"Bober BSaracyn MKo\u0142odziej MKowalski \u0141Deptu\u0142a-Krawczyk EKapusta WKami\u0144ski GMozenska O & Bil J. Carcinoid Heart Disease: How to Diagnose and Treat in 2020?Clinical Medicine Insights. Cardiology2020141179546820968101. (https:\/\/doi.org\/10.1177\/1179546820968101)"},{"key":"bib23","series-title":"Cancers","article-title":"Elevated serotonin and NT-proBNP levels predict and detect carcinoid heart disease in a large validation study","volume":"14","author":"Levy","year":"2022","unstructured":"Levy SKilgallen ABKorse CMOerlemans MIFJSluijter JPGLaake van LWValk GD & Tesselaar MET. Elevated serotonin and NT-proBNP levels predict and detect carcinoid heart disease in a large validation study. Cancers202214. (https:\/\/doi.org\/10.3390\/cancers14102361)"},{"key":"bib24","series-title":"American Journal of Cardiology","first-page":"938","article-title":"Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease","volume":"102","author":"Bhattacharyya","year":"2008","unstructured":"Bhattacharyya SToumpanakis CCaplin ME & Davar J. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. American Journal of Cardiology2008102938\u2013942. (https:\/\/doi.org\/10.1016\/j.amjcard.2008.05.047)"},{"key":"bib25","series-title":"British Journal of Cancer","first-page":"2073","article-title":"Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease","volume":"90","author":"Zuetenhorst","year":"2004","unstructured":"Zuetenhorst JMKorse CMBonfrer JMGBakker RH & Taal BG. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. British Journal of Cancer2004902073\u20132079. (https:\/\/doi.org\/10.1038\/sj.bjc.6601816)"},{"key":"bib26","series-title":"Endocrine Pathology","first-page":"115","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","unstructured":"Rindi GMete OUccella SBasturk ORosa La SBrosens LAAEzzat SHerder de WWKlimstra DSPapotti M, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocrine Pathology202233115\u2013154. (https:\/\/doi.org\/10.1007\/s12022-022-09708-2)"},{"key":"bib27","series-title":"Kardiologia Polska","first-page":"990","article-title":"What do we know about carcinoid heart disease in the present era?","volume":"80","author":"P\u0119czkowska","year":"2022","unstructured":"P\u0119czkowska MKonsek-Komorowska SJKolasi\u0144ska-\u0106wik\u0142a ADKonka MMicha\u0142owska I & \u0106wik\u0142a JB. What do we know about carcinoid heart disease in the present era?Kardiologia Polska202280990\u20131001. (https:\/\/doi.org\/10.33963\/KP.a2022.0222)"},{"key":"bib28","series-title":"Endokrynologia Polska","first-page":"387","article-title":"Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours) [Aktualizacja zalece\u0144 og\u00f3lnych dotycz\u0105cych post\u0119powania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych uk\u0142adu pokarmowego (rekomendowane przez Polsk\u0105 Sie\u0107 Guz\u00f3w Neuroendokrynnych)]","volume":"73","author":"Kos-Kud\u0142a","year":"2022","unstructured":"Kos-Kud\u0142a BFoltyn WMalczewska ABednarczuk TBolanowski MBorowska MChmielik E\u0106wikla JBGisterek IHandkiewicz-Junak D, et al. Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours) [Aktualizacja zalece\u0144 og\u00f3lnych dotycz\u0105cych post\u0119powania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych uk\u0142adu pokarmowego (rekomendowane przez Polsk\u0105 Sie\u0107 Guz\u00f3w Neuroendokrynnych)]. Endokrynologia Polska202273387\u2013454. (https:\/\/doi.org\/10.5603\/EP.a2022.0049)"},{"key":"bib29","series-title":"Journal of Clinical Medicine","article-title":"Circulating neuroendocrine tumor biomarkers: past, present and future","volume":"11","author":"Komarnicki","year":"2022","unstructured":"Komarnicki PMusia\u0142kiewicz JSta\u0144ska AMaciejewski AGut PMastorakos G & Rucha\u0142a M. Circulating neuroendocrine tumor biomarkers: past, present and future. Journal of Clinical Medicine202211. (https:\/\/doi.org\/10.3390\/jcm11195542)"},{"key":"bib30","series-title":"PLoS One","first-page":"e73679","article-title":"The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study","volume":"8","author":"Dobson","year":"2013","unstructured":"Dobson RBurgess MIBanks MPritchard DMVora JValle JWWong CChadwick CGeorge KKeevil B, et al. The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study. PLoS One20138e73679. (https:\/\/doi.org\/10.1371\/journal.pone.0073679)"},{"key":"bib31","series-title":"British Journal of Cancer","first-page":"1703","article-title":"Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality","volume":"111","author":"Dobson","year":"2014","unstructured":"Dobson RBurgess MIValle JWPritchard DMVora JWong CChadwick CKeevi BAdaway JHofmann U, et al. Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality. British Journal of Cancer20141111703\u20131709. (https:\/\/doi.org\/10.1038\/bjc.2014.468)"},{"key":"bib32","series-title":"Journal of Clinical Oncology","first-page":"4293","article-title":"Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor","volume":"27","author":"Korse","year":"2009","unstructured":"Korse CMTaal BGGroot De CABakker RH & Bonfrer JMG. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. Journal of Clinical Oncology2009274293\u20134299. (https:\/\/doi.org\/10.1200\/JCO.2008.18.7047)"},{"key":"bib33","series-title":"JAMA Network Open","first-page":"e2124750","article-title":"Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States","volume":"4","author":"Xu","year":"2021","unstructured":"Xu ZWang LDai SChen MLi FSun J & Luo F. Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States. JAMA Network Open20214e2124750. (https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.24750)"},{"key":"bib34","series-title":"European Journal of Cancer","first-page":"1975","article-title":"Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry","volume":"49","author":"Korse","year":"2013","unstructured":"Korse CMTaal BGVelthuysen Van MLF & Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. European Journal of Cancer2013491975\u20131983. (https:\/\/doi.org\/10.1016\/j.ejca.2012.12.022)"},{"key":"bib35","series-title":"Journal of Clinical Oncology","first-page":"3063","article-title":"One hundred years after \u2018carcinoid\u2019: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","unstructured":"Yao JCHassan MPhan ADagohoy CLeary CMares JEAbdalla EKFleming JBVauthey JNRashid A, et al. One hundred years after \u2018carcinoid\u2019: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology2008263063\u20133072. (https:\/\/doi.org\/10.1200\/JCO.2007.15.4377)"},{"key":"bib36","series-title":"Oncology","first-page":"155","article-title":"Human small cell lung cancer cells produce brain natriuretic peptide","volume":"56","author":"Ohsaki","year":"1999","unstructured":"Ohsaki YGross AJLe PTOie H & Johnson BE. Human small cell lung cancer cells produce brain natriuretic peptide. Oncology199956155\u2013159. (https:\/\/doi.org\/10.1159\/000011957)"},{"key":"bib37","series-title":"Journal of Clinical Medicine","article-title":"N-terminal pro-brain natriuretic peptide plasma levels are associated with intermediate-term follow-up cancer in coronary patients","volume":"10","author":"Tu\u00f1\u00f3n","year":"2021","unstructured":"Tu\u00f1\u00f3n JPello AAce\u00f1a \u00c1Ramos-Cill\u00e1n S & Mart\u00ednez-Milla JGonz\u00e1lez-Lorenzo \u00d3Fuentes-Antras JTar\u00edn NCrist\u00f3bal CBlanco-Colio LM, N-terminal pro-brain natriuretic peptide plasma levels are associated with intermediate-term follow-up cancer in coronary patients. Journal of Clinical Medicine202110. (https:\/\/doi.org\/10.3390\/jcm10184042)"},{"key":"bib38","series-title":"Heart","first-page":"1874","article-title":"Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality","volume":"101","author":"Pavo","year":"2015","unstructured":"Pavo NRaderer MH\u00fclsmann MNeuhold SAdlbrecht CStrunk GGoliasch GGisslinger HSteger GGHejna M, et al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart20151011874\u20131880. (https:\/\/doi.org\/10.1136\/heartjnl-2015-307848)"},{"key":"bib39","series-title":"European Journal of Clinical Investigation","first-page":"388","article-title":"Five cardiac hormones decrease the number of human small-cell lung cancer cells","volume":"35","author":"Vesely","year":"2005","unstructured":"Vesely BASong SSanchez-Ramos JFitz SRAlli AASolivan SMGower WR & Vesely DL. Five cardiac hormones decrease the number of human small-cell lung cancer cells. European Journal of Clinical Investigation200535388\u2013398. (https:\/\/doi.org\/10.1111\/j.1365-2362.2005.01501.x)"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/12\/10\/EC-23-0249.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/12\/10\/EC-23-0249.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/12\/10\/EC-23-0249.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:46:44Z","timestamp":1784555204000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/1495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":39,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.1530\/ec-23-0249","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,8]]}}}